2014
DOI: 10.1016/j.vaccine.2013.11.023
|View full text |Cite
|
Sign up to set email alerts
|

Alterations in immunodominance of Streptococcus mutans AgI/II: Lessons learned from immunomodulatory antibodies

Abstract: Streptococcus mutans Antigen I/II (AgI/II) has been widely studied as a candidate vaccine antigen against human dental caries. In this report we follow up on prior studies that indicated that anti-AgI/II immunomodulatory monoclonal antibodies (MAbs) exerted their effects by destabilizing the native protein structure and exposing cryptic epitopes. We show here that similar results can be obtained by immunizing mice with truncated polypeptides out of the context of an intra-molecular interaction that occurs with… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

0
14
0
1

Year Published

2014
2014
2017
2017

Publication Types

Select...
6
1

Relationship

3
4

Authors

Journals

citations
Cited by 10 publications
(15 citation statements)
references
References 102 publications
(84 reference statements)
0
14
0
1
Order By: Relevance
“…1C) have provided valuable insights into the antigenic regions of the protein as well as into the mechanism of protection observed with anti-P1 antibodies (49,56,75,90,91). We used single molecule force spectroscopy utilizing several different anti-P1 mAbs (Fig.…”
Section: Volume 290 • Number 14 • April 3 2015mentioning
confidence: 99%
“…1C) have provided valuable insights into the antigenic regions of the protein as well as into the mechanism of protection observed with anti-P1 antibodies (49,56,75,90,91). We used single molecule force spectroscopy utilizing several different anti-P1 mAbs (Fig.…”
Section: Volume 290 • Number 14 • April 3 2015mentioning
confidence: 99%
“…Various strategies aimed at preventing dental caries have been attempted on the basis of various criteria: increasing antimicrobial activity [2]; replacement of sucrose with other sweeteners [3]; inhibition of the key matrix-producing enzymeglucosyltransferases either by vaccine approaches [4] or enzymatic inhibitors [5]; and targeting another important surface protein antigen I/II using immunomodulatory monoclonal antibodies [6]. However, in vivo application of these promising approaches is uncertain.…”
Section: Introductionmentioning
confidence: 99%
“…Our crystal structure lends insight into why the N-terminal segment of P1 has such a pronounced impact on its immunogenicity, antigenicity, folding, stability, and adherent function (17,(21)(22)(23)(24)(25)(26), The NA1/ P3C complex contains an elongated alpha/polyproline type II hybrid helix similar to that identified in the crystallized A3VP1 fragment (14), except that in this case it comprises the A1 and P3 repeats rather than the A3 and P1 repeats. In addition, the pre-A region N terminus is found in immediate juxtaposition with the post-P region sequence and extends into the globular C-terminal domains.…”
Section: Discussionmentioning
confidence: 63%
“…Thus, perturbing stability would allow the formation of protective antibodies against epitopes that would not otherwise be immunogenic in the locked structure. In more recent experiments, immunization of mice with P3C alone elicited antibodies capable of inhibiting adherence of S. mutans to immobilized human salivary agglutinin; however, immunization with the P3C/NA1 complex was significantly less effective (21). Taken together, these previous studies suggest that the association between the N-and C-terminal regions of P1 not only stabilizes the protein structure and enhances the adherent function of the C-terminal region, but also acts to mask protective epitopes from the immune system.…”
Section: Discussionmentioning
confidence: 98%